Displaying drugs 3676 - 3700 of 5224 in total
Aconitate Ion
Experimental
OLOMOUCINE II
Experimental
INCB7839
INCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. It represents a potentially important new class of targeted breast cancer therapy. It has shown promising clinical activity in heavily pretreated, refractory breast cancer patients.
Investigational
Indeglitazar
Experimental
Imidafenacin
Imidafenacin is an antispasmodic agent with anticholinergic effects. It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder. It is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical.
Investigational
Isoquercetin
Isoquercetin has been used in trials studying the treatment of Kidney Cancer, Renal cell carcinoma, Advanced Renal Cell Carcinoma, Thromboembolism of Vein in Pancreatic Cancer, and Thromboembolism of Vein VTE in Colorectal Cancer, among others.
Investigational
Idrocilamide
Experimental
Hydroxide ion
Experimental
Carbonate ion
Experimental
IL15-NK Cell
Natural killer (NK) cells can be incubated with ‘feeder cells’ expressing certain cytokines prior to maturation to enhance their activity. In particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor targets that the cell is not normally sensitive to.
Investigational
Ispronicline
Ispronicline is under investigation in clinical trial NCT00109564 (A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI)).
Investigational
Isorhamnetin
Experimental
Iruplinalkib
Investigational
ISTH0036
ISTH0036 is a synthetic 14-mer phosphorothioate antisense oligonucleotide directed against TGF-beta2 mRNA
Investigational
Coco diethanolamide
Investigational
KW-7158
KW-7158 is a tricyclic compound with a non-cholingergic mechanism of action for the treatment of "urinary urgency," "frequent urination" and "urinary incontinence" associated with bladder overactivity (involuntary abnormal contraction of the bladder). The therapeutic effects of KW-7158 in overactive bladder may be due to the activation of A-type K(+) channels...
Investigational
Matched Iupac: … (2S)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-{2,9,9-trioxo-4,9λ⁶-dithiatricyclo[8.4.0.0³,⁷]tetradeca-1(10 …
R-82913
Experimental
Matched Iupac: … (11S)-6-chloro-11-methyl-10-(3-methylbut-2-en-1-yl)-1,3,10-triazatricyclo[6.4.1.0^{4,13}]trideca-4(13 …
Tivirapine
Experimental
Matched Iupac: … (11S)-7-chloro-11-methyl-10-(3-methylbut-2-en-1-yl)-1,3,10-triazatricyclo[6.4.1.0^{4,13}]trideca-4(13 …
Pazufloxacin
Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).
Investigational
Matched Iupac: … (2S)-6-(1-aminocyclopropyl)-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.0⁵,¹³]trideca-5(13),6,8,11 …
Tavilermide
Tavilermide has been investigated for the treatment of Dry Eye Syndromes.
Investigational
Matched Iupac: … carbamoyl]-14-nitro-6,9,12-trioxo-3,4,5,6,7,8,9,10,11,12-decahydro-2H-1,5,8,11-benzoxatriazacyclotetradecin-10 …
ORG-31710
ORG-31710 is a progestational hormone antagonist.
Experimental
Matched Iupac: … (1R,3aS,3bS,5R,10R,11aS)-10-[4-(dimethylamino)phenyl]-5,11a-dimethyl-2,3,3a,3b,4,5,7,8,9,10,11,11a-dodecahydrospiro …
Dexisometheptene mucate
Dexisometheptene mucate is under investigation in clinical trial NCT02423408 (Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-type Headache).
Investigational
Interferon tau
Investigational
Isocitric Acid
Experimental
Displaying drugs 3676 - 3700 of 5224 in total